drugset / Trial / NCT00640848
Almorexant in Primary Insomnia
RandomizedCrossoverQuadruple-blindTreatment
Summary
The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters.
Timeline
- Start
- 2006-05
- Primary completion
- 2007-08
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | almorexant | Small molecule | 50 mg | — |
| Subject | almorexant | Small molecule | 100 mg | — |
| Subject | almorexant | Small molecule | 200 mg | — |
| Subject | almorexant | Small molecule | 400 mg | — |
| Subject | almorexant | Small molecule | 1000 mg | — |